Argos Therapeutics (ARGS) 5.31 $ARGS
Argos Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock and Warrants
GlobeNewswire - Thu Jul 28, 8:23AM CDT
Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos"
, an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer based on the Arcelis(R) technology platform, today announced the pricing of its public offering of 9,090,909 shares of its common stock and accompanying warrants to purchase up to an aggregate of 6,818,181 shares of its common stock at a price of $5.50 per share and accompanying warrant. Argos expects the gross proceeds of the public offering to be $50 million, before deducting underwriter discounts and expenses payable by Argos. All of the shares of common stock and accompanying warrants to be sold in the offering are to be sold by Argos.
ARGS: 5.31 (+0.05)
Argos Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
GlobeNewswire - Wed Jul 27, 3:08PM CDT
Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos", an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer based on the Arcelis(R) technology platform, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of its common stock in an underwritten public offering. All of the securities to be sold in the offering will be offered by Argos.
ARGS: 5.31 (+0.05)
Apple and Hanesbrands fall, LinkedIn and Symantec climb
AP - Mon Jun 13, 3:36PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Monday:
ARGS: 5.31 (+0.05), LNKD: 193.09 (+0.36), EBIO: 3.80 (-0.17), DUK: 85.65 (+0.06), HBI: 26.55 (-0.11), AAPL: 106.05 (+1.84), SYMC: 20.55 (+0.12)
Independent Data Monitoring Committee Recommends Continuation of ADAPT Phase 3 Clinical Trial of AGS-003 in Metastatic Renal Cell Carcinoma Following Interim Data Review
GlobeNewswire - Mon Jun 13, 7:07AM CDT
Positive outcome triggers the second tranche of the Company's previously announced financing agreement
ARGS: 5.31 (+0.05)
Argos Therapeutics to Participate in Jefferies 2016 Healthcare Conference
GlobeNewswire - Wed Jun 08, 3:05PM CDT
Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis technology platform, today announced the company will participate in the Jefferies 2016 Healthcare Conference to be held June 7-10 at the Grand Hyatt in New York City.
ARGS: 5.31 (+0.05)
Earnings Estimates Moving Higher for Argos Therapeutics (ARGS): Time to Buy?
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 7:37AM CDT
Positive earnings estimate revisions, coupled with impressive Zacks Rank has made Argos Therapeutics (ARGS) an interesting choice for the investors.
ARGS: 5.31 (+0.05)
Argos Therapeutics Reports First Quarter 2016 Financial Results and Operational Highlights
GlobeNewswire - Thu May 12, 3:05PM CDT
- Entered into Equity Financing for Up to $60 million -
ARGS: 5.31 (+0.05)
Argos Therapeutics to Host First Quarter 2016 Financial Results Conference Call on Thursday, May 12, 2016
GlobeNewswire - Thu May 05, 7:00AM CDT
Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos", an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies based on the Arcelis(R) technology platform, today announced that the Company's first quarter 2016 financial results will be released after the market close on Thursday, May 12, 2016. Argos executive management will host a conference call beginning at 4:30 p.m. Eastern Time to discuss these results and to answer questions.
ARGS: 5.31 (+0.05)
3 Buy-Ranked Healthcare Stocks Building Momentum Now
Zacks Premium Research - Zacks Investment Research - Mon Apr 25, 3:57PM CDT
These healthcare stocks have posted double digit share price gains over the last month, but we're talking about another kind of momentum that makes these corporations worth betting on.
ARGS: 5.31 (+0.05), INVA: 13.04 (+0.17), VTAE: 10.71 (+0.06), GSK: 45.25 (+0.18)
Insider Bets Paying Off At ARGS As New 52-Week High Reached
MarketNewsVideo.com - Wed Apr 13, 12:13PM CDT
In trading on Wednesday, shares of Argos Therapeutics Inc. touched a new 52-week high of $9.41/share.
ARGS: 5.31 (+0.05)
Surging Earnings Estimates Signal Good News for Argos Therapeutics (ARGS)
Zacks Equity Research - Zacks Investment Research - Wed Apr 13, 7:44AM CDT
Positive earnings estimate revisions, coupled with impressive Zacks Rank has made Argos Therapeutics (ARGS) an interesting choice for the investors.
ARGS: 5.31 (+0.05)
Can The Uptrend Continue for Argos Therapeutics (ARGS)?
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 8:28AM CDT
Investors certainly have to be happy with Argos Therapeutics, Inc. (ARGS) and its short term performance
ARGS: 5.31 (+0.05)
Argos Therapeutics to Participate in 15th Annual Needham Healthcare Conference
GlobeNewswire - Thu Apr 07, 3:05PM CDT
Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis technology platform, today announced the company will participate in the 15 Annual Needham Healthcare Conference to be held April 12-13 at the Westin New York Grand Central in New York City.
ARGS: 5.31 (+0.05)
The Last Time This Company Made A FDA Submission It Ran 2,100%-- Here's Why You Should Be Looking At It Right Now
ACCESSWIRE - Wed Mar 30, 6:00AM CDT
WINDSOR, ON / ACCESSWIRE / March 30, 2016 / The Wealthy Biotech Trader (or "WBT", an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks making news and subsequent market moves, would like to highlight that the maximum gains are made by investors who seek out promising pharma companies before their filing of FDA approval.
AGEN: 5.65 (+0.10), ARGS: 5.31 (+0.05)
CORRECTION -- Argos Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results and Operational Highlights
GlobeNewswire - Tue Mar 29, 5:12PM CDT
In the release issued earlier today by Argos Therapeutics (Nasdaq:ARGS), please note that the "Selected Third Quarter 2015 Financial Results" header should be "Selected Fourth Quarter and Full-Year 2015 Financial Results." All other information in the press release remains the same.
ARGS: 5.31 (+0.05)
Argos Therapeutics reports 4Q loss
Automated Insights - Tue Mar 29, 3:59PM CDT
DURHAM, N.C. (AP) _ Argos Therapeutics Inc. (ARGS) on Tuesday reported a loss of $17.6 million in its fourth quarter.
ARGS: 5.31 (+0.05)
Argos Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results and Operational Highlights
GlobeNewswire - Tue Mar 29, 3:30PM CDT
- Completed Patient Enrollment in Pivotal Phase 3 ADAPT Clinical Trial of AGS-003 in July 2015 -
ARGS: 5.31 (+0.05)
Argos Therapeutics Announces Initiation of a Phase 2 Clinical Trial of AGS-003 for the Treatment of Non-small Cell Lung Cancer in Combination with Standard-of-Care Chemotherapy
GlobeNewswire - Wed Mar 23, 7:00AM CDT
Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos", an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis(R) technology platform, today announced the initiation of an investigator-sponsored Phase 2 clinical trial of AGS-003 in combination with standard platinum-doublet chemotherapy with or without radiation in patients with newly diagnosed Stage 3 non-small cell lung cancer (NSCLC).
ARGS: 5.31 (+0.05)
Argos Therapeutics to Host Fourth Quarter and Full-Year 2015 Financial Results Conference Call on Tuesday, March 29, 2016
GlobeNewswire - Tue Mar 22, 3:05PM CDT
Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos", an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies based on the Arcelis(R) technology platform, today announced that the Company's fourth quarter and full-year 2015 financial results will be released after the market closes on Tuesday, March 29, 2016. Argos executive management will host a conference call beginning at 4:30 p.m. Eastern Time to discuss these results and to answer questions.
ARGS: 5.31 (+0.05)
Argos Therapeutics to Participate in 6th Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference
GlobeNewswire - Tue Mar 22, 7:00AM CDT
Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos", an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis technology platform, today announced the company will participate in the 6 Annual "Cancer Immunotherapy: A Long-Awaited Reality" conference to be held on March 31, 2016 at the Apella Event Space Alexandria Center in New York City.
ARGS: 5.31 (+0.05)
Argos Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock and Warrants
GlobeNewswire - Thu Jul 28, 8:23AM CDT
Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos"
, an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer based on the Arcelis(R) technology platform, today announced the pricing of its public offering of 9,090,909 shares of its common stock and accompanying warrants to purchase up to an aggregate of 6,818,181 shares of its common stock at a price of $5.50 per share and accompanying warrant. Argos expects the gross proceeds of the public offering to be $50 million, before deducting underwriter discounts and expenses payable by Argos. All of the shares of common stock and accompanying warrants to be sold in the offering are to be sold by Argos. ARGS: 5.31 (+0.05)
Argos Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
GlobeNewswire - Wed Jul 27, 3:08PM CDT
Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos"
, an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer based on the Arcelis(R) technology platform, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of its common stock in an underwritten public offering. All of the securities to be sold in the offering will be offered by Argos. ARGS: 5.31 (+0.05)
Apple and Hanesbrands fall, LinkedIn and Symantec climb
AP - Mon Jun 13, 3:36PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Monday:
ARGS: 5.31 (+0.05), LNKD: 193.09 (+0.36), EBIO: 3.80 (-0.17), DUK: 85.65 (+0.06), HBI: 26.55 (-0.11), AAPL: 106.05 (+1.84), SYMC: 20.55 (+0.12)
Independent Data Monitoring Committee Recommends Continuation of ADAPT Phase 3 Clinical Trial of AGS-003 in Metastatic Renal Cell Carcinoma Following Interim Data Review
GlobeNewswire - Mon Jun 13, 7:07AM CDT
Positive outcome triggers the second tranche of the Company's previously announced financing agreement
ARGS: 5.31 (+0.05)
Argos Therapeutics to Participate in Jefferies 2016 Healthcare Conference
GlobeNewswire - Wed Jun 08, 3:05PM CDT
Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis technology platform, today announced the company will participate in the Jefferies 2016 Healthcare Conference to be held June 7-10 at the Grand Hyatt in New York City.
ARGS: 5.31 (+0.05)
Earnings Estimates Moving Higher for Argos Therapeutics (ARGS): Time to Buy?
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 7:37AM CDT
Positive earnings estimate revisions, coupled with impressive Zacks Rank has made Argos Therapeutics (ARGS) an interesting choice for the investors.
ARGS: 5.31 (+0.05)
Argos Therapeutics Reports First Quarter 2016 Financial Results and Operational Highlights
GlobeNewswire - Thu May 12, 3:05PM CDT
- Entered into Equity Financing for Up to $60 million -
ARGS: 5.31 (+0.05)
Argos Therapeutics to Host First Quarter 2016 Financial Results Conference Call on Thursday, May 12, 2016
GlobeNewswire - Thu May 05, 7:00AM CDT
Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"
, an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies based on the Arcelis(R) technology platform, today announced that the Company's first quarter 2016 financial results will be released after the market close on Thursday, May 12, 2016. Argos executive management will host a conference call beginning at 4:30 p.m. Eastern Time to discuss these results and to answer questions. ARGS: 5.31 (+0.05)
3 Buy-Ranked Healthcare Stocks Building Momentum Now
Zacks Premium Research - Zacks Investment Research - Mon Apr 25, 3:57PM CDT
These healthcare stocks have posted double digit share price gains over the last month, but we're talking about another kind of momentum that makes these corporations worth betting on.
ARGS: 5.31 (+0.05), INVA: 13.04 (+0.17), VTAE: 10.71 (+0.06), GSK: 45.25 (+0.18)
Insider Bets Paying Off At ARGS As New 52-Week High Reached
MarketNewsVideo.com - Wed Apr 13, 12:13PM CDT
In trading on Wednesday, shares of Argos Therapeutics Inc. touched a new 52-week high of $9.41/share.
ARGS: 5.31 (+0.05)
Surging Earnings Estimates Signal Good News for Argos Therapeutics (ARGS)
Zacks Equity Research - Zacks Investment Research - Wed Apr 13, 7:44AM CDT
Positive earnings estimate revisions, coupled with impressive Zacks Rank has made Argos Therapeutics (ARGS) an interesting choice for the investors.
ARGS: 5.31 (+0.05)
Can The Uptrend Continue for Argos Therapeutics (ARGS)?
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 8:28AM CDT
Investors certainly have to be happy with Argos Therapeutics, Inc. (ARGS) and its short term performance
ARGS: 5.31 (+0.05)
Argos Therapeutics to Participate in 15th Annual Needham Healthcare Conference
GlobeNewswire - Thu Apr 07, 3:05PM CDT
Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis technology platform, today announced the company will participate in the 15 Annual Needham Healthcare Conference to be held April 12-13 at the Westin New York Grand Central in New York City.
ARGS: 5.31 (+0.05)
The Last Time This Company Made A FDA Submission It Ran 2,100%-- Here's Why You Should Be Looking At It Right Now
ACCESSWIRE - Wed Mar 30, 6:00AM CDT
WINDSOR, ON / ACCESSWIRE / March 30, 2016 / The Wealthy Biotech Trader (or "WBT"
, an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks making news and subsequent market moves, would like to highlight that the maximum gains are made by investors who seek out promising pharma companies before their filing of FDA approval. AGEN: 5.65 (+0.10), ARGS: 5.31 (+0.05)
CORRECTION -- Argos Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results and Operational Highlights
GlobeNewswire - Tue Mar 29, 5:12PM CDT
In the release issued earlier today by Argos Therapeutics (Nasdaq:ARGS), please note that the "Selected Third Quarter 2015 Financial Results" header should be "Selected Fourth Quarter and Full-Year 2015 Financial Results." All other information in the press release remains the same.
ARGS: 5.31 (+0.05)
Argos Therapeutics reports 4Q loss
Automated Insights - Tue Mar 29, 3:59PM CDT
DURHAM, N.C. (AP) _ Argos Therapeutics Inc. (ARGS) on Tuesday reported a loss of $17.6 million in its fourth quarter.
ARGS: 5.31 (+0.05)
Argos Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results and Operational Highlights
GlobeNewswire - Tue Mar 29, 3:30PM CDT
- Completed Patient Enrollment in Pivotal Phase 3 ADAPT Clinical Trial of AGS-003 in July 2015 -
ARGS: 5.31 (+0.05)
Argos Therapeutics Announces Initiation of a Phase 2 Clinical Trial of AGS-003 for the Treatment of Non-small Cell Lung Cancer in Combination with Standard-of-Care Chemotherapy
GlobeNewswire - Wed Mar 23, 7:00AM CDT
Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos"
, an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis(R) technology platform, today announced the initiation of an investigator-sponsored Phase 2 clinical trial of AGS-003 in combination with standard platinum-doublet chemotherapy with or without radiation in patients with newly diagnosed Stage 3 non-small cell lung cancer (NSCLC). ARGS: 5.31 (+0.05)
Argos Therapeutics to Host Fourth Quarter and Full-Year 2015 Financial Results Conference Call on Tuesday, March 29, 2016
GlobeNewswire - Tue Mar 22, 3:05PM CDT
Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"
, an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies based on the Arcelis(R) technology platform, today announced that the Company's fourth quarter and full-year 2015 financial results will be released after the market closes on Tuesday, March 29, 2016. Argos executive management will host a conference call beginning at 4:30 p.m. Eastern Time to discuss these results and to answer questions. ARGS: 5.31 (+0.05)
Argos Therapeutics to Participate in 6th Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference
GlobeNewswire - Tue Mar 22, 7:00AM CDT
Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos"
, an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis technology platform, today announced the company will participate in the 6 Annual "Cancer Immunotherapy: A Long-Awaited Reality" conference to be held on March 31, 2016 at the Apella Event Space Alexandria Center in New York City. ARGS: 5.31 (+0.05)
